A crop of anti-pain meds rigged to thwart abuse

While anti-pain drugs are a multibillion-dollar business for pharmaceutical firms, some of the treatments such as oxycodone have been abused. This has created a market for technologies that are intended to prevent people from tampering with such pain meds for recreational use--or abuse. Seeking Alpha recently took a deep dive into several approved or late-stage anti-pain meds that feature systems to prevent abuse, with overviews of drug developers such as Acura Pharmaceuticals ($ACUR), Durrect ($DRRX), and Pfizer's ($PFE) King Pharmaceuticals. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.